

**ASX Announcement | 3 March 2020**  
**Visioneering Technologies (ASX:VTI)**

## **Visioneering Technologies, Inc. Appoints Senior Life Sciences Executive David J. Mazzo, PhD as Chairman**

### **Highlights**

- Appointed Dr. David J. Mazzo, Ph.D. as Chairman of the Board of Directors
- Dr. Mazzo is a highly accomplished and experienced life sciences executive and board director
- Dr. Mazzo is currently President, CEO and Executive Director of Caladrius Biosciences, Inc. (NASDAQ: CLBS)
- He also serves on the Boards of Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT) and Seneca Biopharmaceuticals, Inc. (NASDAQ: SNCA)
- Visioneering announced strong revenue growth for 2019 and continues to pursue its global expansion plans, with sales of its product recently commencing in Singapore

**Atlanta, Georgia, USA 2 March 2020:** Visioneering Technologies, Inc (ASX: VTI), a US-based medical device company ('Visioneering' or 'The Company') engaged in the design, manufacture, sale and distribution of its proprietary NaturalVue™ Multifocal 1 Day (NaturalVue MF) contact lenses, is pleased to announce the appointment of Dr. David J. Mazzo, Ph.D. to its Board of Directors as Chairman of the Board.

Dr. Mazzo is a highly accomplished and experienced life sciences executive and board director with almost 40 years of experience in managing medical device and pharmaceutical companies. He will replace former Visioneering Chairman Fred Schwarzer, who resigned from the Board effective 31 December 2019.

Dr. Mazzo is currently President, CEO and Executive Director of Caladrius Biosciences, Inc. (NASDAQ: CLBS). He also serves on the boards of Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT), and Seneca Biopharmaceuticals, Inc. (NASDAQ: SNCA). Previously, Dr. Mazzo served as CEO and Executive Director of Regado Biosciences, Inc., where, among other accomplishments, he led Regado's IPO.

*Dr. David J. Mazzo*



Prior to leading Regado, Dr. Mazzo was CEO and Executive Director of Aeterna Zentaris (NASDAQ: AEZS, TSX: AEZS), and of Chugai Pharma USA, LLC, the U.S. subsidiary of Japan's Chugai Pharmaceuticals Co. Ltd. (TYO: 4519), a member of the Roche group (SWX:RO). Dr. Mazzo has also had a distinguished international career leading pharmaceutical development for Rhone-Poulenc Rorer and Hoechst Marion Roussel culminating in his position as Senior Vice President of Development Operations for Schering-Plough Research Institute.

Dr. Mazzo's academic training and early career were in analytical chemistry. He received his Ph.D. degree in Analytical Chemistry from the University of Massachusetts Amherst, and completed a research fellowship at the Ecole Polytechnique Federale de Lausanne in Switzerland. He earned a BA in the Honors program (interdisciplinary humanities) and a BS in chemistry at Villanova University.

Visioneering recently announced strong results for the December quarter, with unaudited net revenue increasing 31% quarter on quarter and 81% over the prior corresponding period to US\$1.9m [ASX Announcement: 10 January 2020]. The Company also continues to pursue its global growth plans, with sales of its NaturalVue Multifocal lenses recently commencing in Singapore [ASX Announcement: 5 February 2020]. The expansion into Singapore follows a successful entry into Hong Kong in Q3 2019.

**Visioneering's CEO, Dr. Stephen Snowdy said:** "Dr. Mazzo brings to Visioneering's board a wealth of knowledge and experience in managing public life sciences companies in all phases, from early startup to mature public companies. Visioneering and our shareholders are very fortunate to have access to the knowledge and judgement born of Dr. Mazzo's many years as an executive and board member. I would also like to take this opportunity to wish outgoing Chairman Fred Schwarzer all the best as he turns his full-time attention to his now public IGM Biosciences, Inc."

**Ends.**

This release was authorised by the CEO & Managing Director as described below.

**For more information, please contact:**

**Visioneering Technologies**

**Stephen Snowdy**

CEO & Managing Director

E: [ssnowdy@vtivision.com](mailto:ssnowdy@vtivision.com)

**Investor & Media Relations**

**Julia Maguire**

The Capital Network

M: +61 419 815 386

E: [julia@thecapitalnetwork.com.au](mailto:julia@thecapitalnetwork.com.au)

**NaturalVue® (etafilcon A) Multifocal 1 Day Contact Lens Indication for Use in Europe and Australia and New Zealand:** NaturalVue (etafilcon A) Multifocal Daily Disposable Soft (Hydrophilic) Contact Lenses are indicated for daily wear for the correction of refractive ametropia (myopia and hyperopia) and/or presbyopia, and myopia progression control in aphakic and/or non-aphakic persons with non-diseased eyes in powers from -20.00 to +20.00 dioptres and with non-diseased eyes who may require a reading addition of up to +3.00D. The lenses may be worn by persons who exhibit astigmatism of 2.00 dioptres or less that does not interfere with visual acuity.

### About Visioneering Technologies

Visioneering Technologies Inc. (ASX:VTI) is an innovative eye care company committed to redefining vision. Since its founding in 2008, Visioneering has brought together clinical, marketing, engineering, manufacturing and regulatory leaders from top vision care businesses to provide new solutions for presbyopia, myopia and astigmatism.

Headquartered in the US, Visioneering designs, manufactures, sells and distributes contact lenses. Its flagship product is the NaturalVue® Multifocal contact lens, and VTI has expanded its portfolio of technologies to address a range of eye care issues. The company has grown operations across the United States, Australia and Europe and is expanding into Asia with a focus on markets with high rates of myopia.

### Foreign Ownership Restrictions

VTI's CHES Depositary Interests (**CDIs**) are issued in reliance on the exemption from registration contained in Regulation S of the US Securities Act of 1933 (**Securities Act**) for offers which are made outside the US. Accordingly, the CDIs have not been, and will not be, registered under the Securities Act or the laws of any state or other jurisdiction in the US. As a result of relying on the Regulation S exemption, the CDIs are 'restricted securities' under Rule 144 of the Securities Act. This means that you are unable to sell the CDIs into the US or to a US person for the foreseeable future except in very limited circumstances after the expiration of a restricted period, unless the re-sale of the CDIs is registered under the Securities Act or an exemption is available. To enforce the above transfer restrictions, all CDIs issued bear a 'FOR US' designation on the Australian Securities Exchange (**ASX**). This designation restricts any CDIs from being sold on ASX to US persons. However, you are still able to freely transfer your CDIs on ASX to any person other than a US person. In addition, hedging transactions with regard to the CDIs may only be conducted in accordance with the Securities Act.

### Forward-Looking Statements

This announcement contains or may contain forward-looking statements that are based on management's beliefs, assumptions and expectations and on information currently available to management.

All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements. These include, without limitation, U.S. commercial market acceptance and U.S. sales of our product as well as our expectations with respect to our ability to develop and commercialize new products.

Management believes that these forward-looking statements are reasonable when made. You should not place undue reliance on forward-looking statements because they speak only as of the date when made. VTI does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. VTI may not actually achieve the plans, projections or expectations disclosed in forward-looking statements. Actual results, developments or events could differ materially from those disclosed in the forward-looking statements.

VTI-IR-ASX20